A COST-UTILITY ANALYSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN THE NETHERLANDS: REDUCED HYPOPHOSPHATEMIA AND FRACTURE INCIDENCE WITH FERRIC DERISOMALTOSE VERSUS FERRIC

被引：0

作者：

Oron, U. ^{[1
]}

Koek, G. ^{[2
]}

Fijn, R. ^{[3
]}

Pollock, R. ^{[4
]}

机构：

[1] C3 Consultancy Cooperat, Egmond Aan Zee, Netherlands

[2] Maastricht Univ, Med Ctr, Maastricht, Limburg, Netherlands

[3] Alrijne Healthcare Grp, Leiden, South Holland, Netherlands

[4] Covalence Res Ltd, Harpenden, Herts, England

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE314

引用

页码：S116 / S116

页数：1

共 50 条

[21] Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose
Hu, Shanlian
Liu, Limin
Pollock, Richard F.
Pohlmann, Johannes
Wu, Depei
Zhang, Yabing
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 561 - 570
[22] Ferric derisomaltose versus usual care in patients with heart failure, reduced ejection fraction, and iron deficiency: a short-term UK cost-utility analysis based on the IRONMAN RCT
Pollock, R.
Kalra, P. R.
Mcmurray, J. J., V
Graham, F. J.
Pellicori, P.
Cleland, J. G. F.
Ford, I
EUROPEAN HEART JOURNAL, 2024, 45
[23] AN ECONOMIC EVALUATION OF IRON ISOMALTOSIDE 1000 VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN DENMARK
Pollock, R. F.
Muduma, G.
VALUE IN HEALTH, 2018, 21 : S443 - S444
[24] An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
Richard F. Pollock
Gorden Muduma
Advances in Therapy, 2018, 35 : 2128 - 2137
[25] An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
Pollock, Richard F.
Muduma, Gorden
ADVANCES IN THERAPY, 2018, 35 (12) : 2128 - 2137
[26] COST-EFFECTIVENESS OF FERRIC CARBOXYMALTOSE (FCM) IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Walter, E.
Lazic-Peric, A.
Schalle, K.
VALUE IN HEALTH, 2017, 20 (09) : A634 - A635
[27] Efficacy and Safety of Ferric Derisomaltose/Iron Isomaltoside in Patients with Inflammatory Bowel Disease: A Systematic Review
Sam, Keren
Khan, Atif Irfan
Khan, Anam
Aamir, Sobia
Sajid, Fatima
Nasir, Yusra Minahil
Arslan, Muhammad
Asad, Muhammad
Anwer, Faiz
BLOOD, 2021, 138
[28] Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
Pollock, Richard F.
Muduma, Gorden
ADVANCES IN THERAPY, 2019, 36 (08) : 1821 - 1825
[29] Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
Zoller, Heinz
Wolf, Myles
Blumenstein, Irina
Primas, Christian
Lindgren, Stefan
Thomsen, Lars L.
Reinisch, Walter
Iqbal, Tariq
GUT, 2023, 72 (04) : 644 - 653
[30] Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
Ayşegül Aksan
Axel Dignass
Jürgen Stein
Advances in Therapy, 2019, 36 : 1817 - 1820

← 1 2 3 4 5 →